TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blinded,Double-dummy Clinical Trial of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* either gender aged 18 to 65 years~* have FC diagnosed as Rome III criterial~* have diagnosis of Excessive Constipation according to the TCM theory~* complete spontaneous bowel movement (CSBM) ≦2times/w~* severity of constipation≧3pts (7 pts scale from 0 to 6pts) and the overall scoring of constipation-related symptoms≧6pts (6items in 7pts scale) for self symptom assessment in the run-in period~* normal colonic evaluation (colonoscopy or barium enema) within 12 months~* normal liver and renal function in blood test within 3 months~Exclusion Criteria:~* drug-induced constipation~* secondary causes of constipation (i.e. medical history of diabetes mellitus and thyroid disease)~* abdominal surgery (i.e. Caesarean operation)~* severe diseases (i.e. cancer and acute present asthma)~* allergy to CHM (i.e. G6PD deficiency), senna and tartrazine~* pregnancy or breast-feeding~* psychiatric or addictive disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MZRW (Type: EXPERIMENTAL): MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
- Senna (Type: ACTIVE_COMPARATOR): Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo MZRW and Placebo Senna

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* Able to comprehend, sign, and date the written informed consent form~* English as primary language~* Undergoing a non-emergent EGD or colonoscopy~* Have taken nothing by mouth for a minimum of 6 hours prior to the study procedure~* American Society of Anesthesiologists (ASA) Class I, II or III~Exclusion Criteria:~* Allergy or inability to tolerate study medications or components of study medications~* Investigator anticipates greater than 45 minute procedure time due to known anatomical difficulty~* Currently using a fentanyl patch~* History of diagnosed sleep apnea~* History of diagnosed gastroparesis~* Baseline oxygen saturation \< 90% (room air)~* Pregnant or nursing females~* Body mass index (BMI) ≥ 35~* Participation in a clinical trial within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sedation System (Type: EXPERIMENTAL): Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
- Current Standard of Care (Type: ACTIVE_COMPARATOR): Site's current standard used for delivery of sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Healthy volunteers aged between 18 to 50 years.~2. Body mass index (BMI) between 18 and 30 kg/m2.~3. Female subjects must:~   * be of childbearing potential with a negative serum β-human chorionic gonadotropin (β-HCG) test at screening, and be willing and able to use medically acceptable double barrier methods of birth control, throughout the whole study; or~  * be postmenopausal; or~  * have received surgical sterilisation at least 6 months before screening; AND~  * females must not be receiving hormone replacement therapy (HRT).~Main exclusion Criteria:~1. Abnormal QTcF and/or heart rate/blood pressure values at baseline.~2. Subjects with ECG abnormalities that may interfere with the accurate assessment of the QT interval.~3. Subjects with known cardiovascular disorders.~4. Subjects with known clinically significant arrhythmias.~5. Subjects with risk factors e.g., Torsades de Pointes.~6. Subjects with clinically relevant, abnormal serum electrolytes or complete blood count (CBC) at screening.~7. Female subjects who are lactating or pregnant.~8. Subjects suffering from other significant medical conditions.~9. Subjects with a known allergy or sensitivity to moxifloxacin, or to prucalopride.~10. Subjects with a positive screening test for hepatitis B, hepatitis C, or HIV at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Prucalopride
- 2 (Type: PLACEBO_COMPARATOR): Placebo/moxifloxacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Asymmetric And Standard Split-Dose Regimen For Bowel Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients scheduled as outpatient for screening or surveillance colonoscopy~Exclusion Criteria:~* Inpatients~* refusal of split dose regimen for bowel preparation~* previous history of colorectal resection~* severe cardiac disease~* advanced (stage IV and V) chronic kidney disease~* pregnancy; ileus~* suspected bowel obstruction or toxic megacolon~* known inflammatory bowel disease~* known or suspected allergy to PEG.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Asymmetric split dose preparation (Type: EXPERIMENTAL): 75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
- Symmetric split dose preparation (Type: ACTIVE_COMPARATOR): 50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above~Exclusion Criteria:~* Previous exposure to anti-IL 12

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): ABT-874
- B (Type: ACTIVE_COMPARATOR): Methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged over 19 years~* Signed informed consent~* At visit 1, LDL-C ≤ 250mg/dL and Triglyceride \< 400 mg/dL~* After 4 weeks more TLC, At visit2, LDL-C ≤ 250mg/dL, Triglyceride \< 400 mg/dL and satisfied criteria according to Risk of cardiovascular disease~Exclusion Criteria:~* Current or past history of hypersensitivity to HMG-CoA reductase inhibitors and component of Ezetimibe~* Has an active liver disease and severe liver disorder (continous elevation of AST, ALT level or exceeds more than 3 times of normal upper limit)~* Has a severe renal failure and kidney injury (Creatinine level exceeds more than 2 times of normal upper limit)~* CK level exceeds more than 5 times of normal upper limit~* Uncontrolled hypertension patient (SBP≥ 180 mmHg or DBP ≥ 110 mmHg)~* Uncontrolled diabetes mellitus patient (HbA1c ≥ 9%)~* Uncontrolled malfunctional thyroidism (or at pre-visit 2, TSH level exceeds more than 1.5 times of normal upper limit)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGP0816 5mg (Type: ACTIVE_COMPARATOR): None
- HGP0816 10mg (Type: ACTIVE_COMPARATOR): None
- HGP0816 20mg (Type: ACTIVE_COMPARATOR): None
- HCP1306 5/10mg (Type: EXPERIMENTAL): None
- HCP1306 10/10mg (Type: EXPERIMENTAL): None
- HCP1306 20/10mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C, genotype 4-infection (hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] level greater than 1,000 IU/mL at Screening)~* Subjects must meet one of the following:~  * Treatment-naive: Subject has never received antiviral treatment for HCV infection OR~ * Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegylated-interferon \[pegIFN\]/RBV);~* Females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control~* In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan~* In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with Child-Pugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma~Exclusion Criteria:~* Females who are pregnant or breastfeeding~* Positive screen for hepatitis B Surface antigen or anti-Human Immunodeficiency virus antibody~* HCV genotype performed during screening indicating unable to genotype or co-infection with any other HCV genotype~* abnormal laboratory tests~* self-reports current drinking more than 2 drinks per day~* current enrollment in another investigational study~* previous treatment with a direct acting antiviral agent (DAA) containing regimen~* In substudy 1, evidence of liver cirrhosis~* In substudy 2, evidence of current or past Child-Pugh B or C classification and confirmed presence of hepatocellular carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent \[DAA\]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
- Arm B (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
- Arm C (Type: ACTIVE_COMPARATOR): ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria will include all HCA hospitals that reside in US states where physicians do NOT routinely prescribe decolonization for MRSA + ICU patients.~Exclusion Criteria:~* Exclusion criteria will include hospitals where ICU physicians often prescribe decolonization for MRSA+ ICU patients.~* Dedicated burn ICUs will also be excluded due to the inability to perform routine bathing.~* Finally, since the intent is to assess the intervention in adult ICUs, pediatric hospitals will be excluded although patients \<13 years old that are admitted to participating adult ICUs will be included in the unit-based intervention.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Usual Care-Active Surveillance (Type: NO_INTERVENTION): Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
- Arm 2: Targeted Decolonization (Type: ACTIVE_COMPARATOR): Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
- Arm 3: Universal Decolonization (Type: ACTIVE_COMPARATOR): Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the Week 24 visit and the 6-Week Follow-up visit of Corcept Study C-1073-400 (NCT00569582).~* In the opinion of the Investigator, are expected to maintain clinical benefit from mifepristone.~* Women of childbearing potential have a negative serum pregnancy test at Entry.~* Women of childbearing potential must be willing to use non-hormonal, medically acceptable methods of contraception during the study.~* Are able to provide written informed consent~* Are able to return to the investigative site to complete the study evaluations outlined in the protocol.~* Will not use systemic estrogens during the study.~Exclusion Criteria:~* Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.~* Are taking medications within 14 days of the Entry visit that a) have a large first pass metabolism that is largely mediated by CYP3A4 and which have a narrow therapeutic margin; and/or b) are strong CYP3A4 inhibitors.~* Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.~* Have received investigational treatment (drug, biological agent or device) other than CORLUX (mifepristone) within 30 days of Entry~* Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)~* Have uncorrected hypokalemia (potassium level of \<3.5 mEq/L) at Entry. Spironolactone or eplerenone is allowed to control hypokalemia.~* Postmenopausal women with a history of endometrial hyperplasia with atypia or pathological features consistent with endometrial carcinoma.~* Thickened endometrium on the Entry Visit transvaginal ultrasound that has not resolved after induction of menstrual bleeding with progesterone.~* Uncontrolled, clinically significant hypothyroidism or hyperthyroidism.~* Any woman with an intact uterus who has a hemorrhagic disorder or is being treated with an anticoagulant (e.g. warfarin, heparin).~* Have renal failure as defined by a serum creatinine of ≥2.2 mg/dL.~* Elevated total bilirubin \>1.5 ULN, elevated ALT or AST ≥3X the upper limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Mifepristone 300mg to 1200mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TevaGastrim for Stem Cell Mobilization Sibling Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 70 years.~2. Normal sibling donor that is HLA matched to a patient with AML or MDS that needs and is eligible for allogeneic stem cell transplantation~3. Written informed consent.~Exclusion Criteria:~1. Inability to tolerate PBPC harvest.~2. Peripheral venous access not possible.~3. Positive pregnancy test for female donors.~4. Positive serology for hepatitis C and/or HBSAg, unless negative for antigen PCR.~5. Psychiatric, addictive, or any disorder which compromises ability to give truly informed consent for participation in this study.~6. Treatment with other investigational drugs.~7. Known sensitivity to CHO derived products.~8. HIV positive.~9. History of malignant disease or current malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- TevaGastrim (Type: EXPERIMENTAL): treatment with TevaGastrim for allogeneic stem cell collection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Participant was \>8 months of age at the time of dosing.~2. Confirmation of LAL-D diagnosis as determined by the central laboratory or, for participants with prior hematopoietic stem cell transplant or liver transplant, historical enzyme activity or molecular genetic testing confirming a diagnosis of LAL-D.~3. Participants \>8 months but \<4 years of age at Screening had at least 1 of the following documented clinical manifestations of LAL-D:~   * Dyslipidemia~  * Elevated transaminases~  * Impaired growth~  * Suspected malabsorption~  * Other clinical manifestation of LAL-D~4. Participants ≥4 years of age at Screening had at least 1 of the following documented clinical manifestations of LAL-D:~   * Evidence of advanced liver disease~  * Histologically confirmed disease recurrence in participants with past liver or hematopoietic transplant~  * Persistent dyslipidemia~  * Suspected malabsorption~  * Other clinical manifestation of LAL-D~Key Exclusion Criteria:~1. Participant had known causes of active liver disease other than LAL-D, which had not been adequately treated.~2. Participant received a hematopoietic stem cell or liver transplant \<2 years from the time of dosing.~3. Participant with co-morbidities other than complications due to LAL-D, which were irreversible or associated with a high mortality risk within 6 months or would interfere with study compliance or data interpretation.

- Gender: ALL
- Minimum Age: 8 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sebelipase Alfa (Type: EXPERIMENTAL): Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Hypertonic Saline for Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of viral bronchiolitis~* between November and April~Exclusion Criteria:~* prematurity \< 34 weeks~* chronic lung disease~* congenital heart disease~* history of wheezing, asthma or albuterol use~* tracheostomy status~* need for intensive care of assisted ventilation

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Nebulized 3% Saline (Type: EXPERIMENTAL): 3% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.
- Nebulized 0.9% Saline (Type: PLACEBO_COMPARATOR): 0.9% NaCl, 4 mL inhalation, up to 3 inhalations every 20 minutes in the ED, and Q8H in the inpatient setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete